VFPI
TEVA icon

Vantage Financial Partners (Illinois)’s Teva Pharmaceuticals TEVA Stock Holding History

Vantage Financial Partners (Illinois)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-24,000
Closed -$370K – 86
2018
Q4 		$370K Buy
+24,000
New +$492K 0.27% 48
2017
Q4 		– Sell
-3,100
Closed -$279K – 84
2017
Q3 		$279K Buy
+3,100
New +$69.8K 0.2% 54

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vantage Financial Partners (Illinois)'s TEVA Position: Q1 2019 in Review

Vantage Financial Partners (Illinois) sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 24,000 shares — an estimated $370K sold.

Vantage Financial Partners (Illinois) first reported a position in TEVA in Q3 2017 and held it in 2 quarters. The position peaked at $370K in Q4 2018. 522 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

  • Vantage Financial Partners (Illinois) reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Vantage Financial Partners (Illinois) sold 24,000 Teva Pharmaceuticals shares in Q1 2019, an estimated $370K.
  • Vantage Financial Partners (Illinois) first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Vantage Financial Partners (Illinois)'s Teva Pharmaceuticals position peaked at $370K in Q4 2018.
  • 522 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Vantage Financial Partners (Illinois)'s 13F filing for Q1 2019, filed 9 May 2019.